US $690 million acquisition, Edwards lifesciences again launched the field of transcatheter heart valve therapy

Source: AON 2016-11-30 Edwards lifesciences, a medical equipment company based in Irvine, California, recently put more and more bets on transcatheter treatment of mitral valve Edwards, who focuses on structural heart disease and dominates the U.S market for transcatheter valve replacement equipment, recently announced a $690 million acquisition of Israeli company valtech cardio Valtech has a product called "cardiobandtm system" that uses transcatheter therapy to repair heart valves Valtech is regarded by Edwards lifesciences as the cardiobandtm system cardiac transcatheter therapy, which is a kind of technology that can insert catheter from peripheral blood vessels and send it to cardiac cavity and big blood vessels It can perform minimally invasive treatment for structural heart disease, and even is considered as a "non-surgical" method Previously acquired by Edwards lifesciences, cardiaq has developed the world's first self-tuning and self anchoring technology for catheter-implanted mitral valve (TMVI) By the beginning of 2017, Edwards will deliver $340 million in stock and cash to valtech, and will pay the remaining $350 million over the next 10 years in the form of phased payments Both parties have not disclosed the form of periodic payment, but generally, Edwards lifesciences and other companies will regularly assess the acquired company after acquisition, check the approval compliance of new products, market revenue, etc., and decide whether to give the next appropriation through each inspection result "We are pleased to see that Edwards, a leading medical equipment company in the world, has focused on the field of transcatheter therapy for structural heart disease We believe that this cooperation will enable valtech's cardioband products to fully play their potential in the treatment of mitral regurgitation " Amir gross, CEO of valtech cardio, said In patients with mitral regurgitation, the left ventricle is enlarged, which leads to the dysfunction of papillary muscle of the ventricle, which leads to the dysfunction of the mitral valve and the mitral annulus Eventually, it can lead to poor valve leaf activity, blood flow, and even lead to heart disease in severe cases For patients with functional mitral regurgitation, valtech's cardiobandtm system is different from the traditional heart surgery in its treatment method Instead, it uses the way of catheter to reconstruct the filling The cardiobandtm system uses the technique of femoral vein puncture, i.e the catheter goes through the femoral vein, through the diaphragm and into the heart In particular, the device to repair the mitral annulus is customized for each patient Heart valve therapy can be performed by femoral vein puncture "In the process of continuous exploration of treatment methods for related diseases, we found that valtech's products can supplement our comprehensive series of heart valve repair and replacement devices," said Michael mussallem, chairman and CEO of Edwards“ There are many projects being carried out within the company, and their current progress and prospects are considerable We also believe that valtech's excellent team and heart valve technology can bring us more opportunities " Last year, Edwards launched its transcatheter heart valve replacement program after buying cardiaq for about $400 million This is one of the internal projects mentioned by musallem There are two ways of valve replacement through the cardiaq system: one is the reverse way, through the femoral vein on the thigh into the ventricle; the other is the forward way, directly through the apex of the heart Edwards lifesciences didn't want to buy a company to study mitral valve replacement technology alone, but because valtech can optimize cardiaq's valve, Edwards really decided to accumulate resources in the field of heart valve, so he decided to buy valtech again Prior to the completion of the acquisition, valtech will temporarily delay its early research project of transcatheter mitral valve replacement Founded in 2005, valtech cardio is a private enterprise specializing in the repair and replacement of mitral and tricuspid valves It has obtained and is applying for more than 150 patents In addition to the cardiobandtm system that Edwards likes, they also have a set of surgical valve repair combination and a cardiovalvetm transcatheter valve replacement system under development In the whole process of R & D, manufacturing and clinical research, valtech cardio has its own resources.